[CAS NO. 1449598-06-4]  RG7800

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1449598-06-4]

Fulfillment
Catalog
AS940026
Brand
Arctom Scientific
CAS
1449598-06-4

DESCRIPTION [1449598-06-4]

Overview

MDLMFCD31382130
Molecular Weight416.52
Molecular FormulaC24H28N6O
SMILESO=C1C=C(C2=NN3C(C(CC)=NC(C)=C3)=C2)N=C4N1C=C(C5CCN(C)CC5)C=C4C

For research use only. We do not sell to patients.


Summary

RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.


In Vitro

RG7800 increases the SMN protein level via induction of alternative splicing of the SMN2 mRNA. RG7800 is shown to promote the inclusion of exon 7 in SMN2 mRNA, generating full-length mRNA in vitro using fibroblasts from an SMA type I patient [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

RG7800 shows favorable drug metabolism and pharmacokinetic profile in the rat and in cynomolgus monkey with good oral bioavailability. In SMA mouse model, treatment of RG7800 shows a clear dose dependent increase in SMN protein levels. Mice treated with RG7800 demonstrate a dose dependent increase in survival beginning at the low dose (0.3/1 mg/kg). In the middle and high dose groups (1/3 and 3/10 mg/kg, respectively), approximately 80−90% survive beyond PND50/PND60 with profound body weight gain when the study is terminated. RG7800 dose-dependently corrects SMN2 splicing by including exon 7 to create FL mRNA, suggesting that RG7800 corrects alternative splicing of the human SMN2 gene in the brain of transgenic SMA model mice, leading to an increase of the SMN protein in the brain [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02240355 Hoffmann-La Roche
Muscular Atrophy, Spinal
November 2014 Phase 1

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

Ethanol : 2.5 mg/mL ( 6.00 mM ; Need ultrasonic)

DMSO : 1.4 mg/mL ( 3.36 mM ; Need ultrasonic and warming)

H 2 O : 1.25 mg/mL ( 3.00 mM ; ultrasonic and adjust pH to 3 with HCl)

H 2 O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4008 mL 12.0042 mL 24.0085 mL
5 mM 0.4802 mL 2.4008 mL 4.8017 mL
10 mM --- --- ---
* Please refer to the solubility information to select the appropriate solvent.